Skip to main content
Premium Trial:

Request an Annual Quote

Curtis Keith, Dave Tapolczay

Premium
Harvard University’s Office of Technology Development said this week that it has appointed Curtis Keith as chief scientific officer for the Accelerator Fund.
 
Keith will manage the life science R&D projects supported by the Accelerator, including ensuring that funded projects stay on course and meet development milestones. He joins Harvard’s OTD from CombinatoRx, where he served as co-founder and senior vice president of research. He obtained a PhD in chemistry and chemical biology and an MA in chemistry from Harvard, and holds a BS in biochemistry from McGill University.
 

 
Dave Tapolczay has been named the new director of MRC Technology, the tech-transfer company of the UK Medical Research Council.
 
Tapolczay previously worked as vice president of technology development at GlaxoSmithKline Pharmaceuticals, and has also served as CEO of StylaCats and Pharmophix.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.